Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II randomized double-blind multicenter study of A82/B86 human anti-tetanus toxin monoclonal antibody injection for tetanus prevention
CTR20241600Phase 2Completed
- Sponsor
- Changchun Baimu Biotechnology
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CBL8851 in Tetanus, sponsored by Changchun Baimu Biotechnology. Started May 2024; status: completed.
02
Drugs
CBL8851
03
Conditions
Tetanus
Beyond the preview
Go deeper on CTR20241600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241600.